← Leaderboards
Robin Polt
University Of Arizona
$3,594,762
Attributed
$3,594,762
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $448.3K · FY2007–19$500K$375K$250K$125K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$3,594,762 · 2
By mechanism
R01$3,594,762 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Arizona
Same institution · by research overlap
- Heddwen L Brooks$3,300,351
- John Michael Streicher$5,241,021
- Thomas Paul Davis$16,406,885
- Henry I Yamamura$2,942,800
- Frank Porreca$26,550,739
Others in their field
Top investigators on “Rodent Model”
- David Heimbrook · Leidos Biomedical Research, Inc.$173,257,325
- Polly Chang · Sri International$53,674,299
- Ed Lein · Allen Institute$41,433,793
- Neil Scott Lipman · Sloan-Kettering Inst Can Research$39,869,247
- Hongkui Zeng · Allen Institute$37,381,292
- Karl Alexander Deisseroth · Stanford University$35,775,407
Research focus
Rodent ModelPharmaceutical PreparationsPharmacologyGlycopeptidesPenetrationOpioid ReceptorPeptidesGlycosylationDynorphinsEvaluationLaboratoriesIn VivoAgonistNeuropeptidesDrug DesignBrainDesignBaseDrug DevelopmentDrug KineticsEndorphinsEnkephalinsBlood - Brain Barrier AnatomyAdverse Effects
Grant awards (10)
PACAP/VIP Glycopeptide Agonists as Neuroprotective Therapies for Parkinson's Disease$373,274
R01 · FY2019 · NS · contact PI
PACAP/VIP Glycopeptide Agonists as Neuroprotective Therapies for Parkinson's Disease$379,606
R01 · FY2018 · NS · contact PI
PACAP/VIP Glycopeptide Agonists as Neuroprotective Therapies for Parkinson's Disease$448,260
R01 · FY2017 · NS · contact PI
PACAP/VIP Glycopeptide Agonists as Neuroprotective Therapies for Parkinson's Disease$432,505
R01 · FY2016 · NS · contact PI
PACAP/VIP Glycopeptide Agonists as Neuroprotective Therapies for Parkinson's Disease$398,313
R01 · FY2015 · NS · contact PI
BIOUSIAN GLYCONEUROPEPTIDE AMPHIPATHS PENETRATE THE BBB$304,284
R01 · FY2011 · NS · contact PI
BIOUSIAN GLYCONEUROPEPTIDE AMPHIPATHS PENETRATE THE BBB$306,306
R01 · FY2010 · NS · contact PI
BIOUSIAN GLYCONEUROPEPTIDE AMPHIPATHS PENETRATE THE BBB$305,006
R01 · FY2009 · NS · contact PI
BIOUSIAN GLYCONEUROPEPTIDE AMPHIPATHS PENETRATE THE BBB$304,053
R01 · FY2008 · NS · contact PI
BIOUSIAN GLYCONEUROPEPTIDE AMPHIPATHS PENETRATE THE BBB$343,155
R01 · FY2007 · NS · contact PI